MindImmune Secures $5 Million ADDF Investment to Advance First-in-Class Alzheimer's Immunotherapy MITI-101
Key Insights
MindImmune (search) received a $5 million strategic investment from the Alzheimer's Drug Discovery Foundation (search) to accelerate development of MITI-101 (search), a first-in-class therapeutic targeting immune pathways (search) in Alzheimer's disease (search).
MITI-101 (search) is designed to intervene upstream in immune pathways (search) that drive neuroinflammation (search) and neurodegeneration (search), addressing mechanisms that contribute to sustained neuroinflammatory damage in Alzheimer's patients.
The funding will support completion of critical translational studies and IND submission, as well as strategic planning for early clinical development of this novel immune-focused approach.
MindImmune (search), a Cambridge-based biotechnology company, has secured a transformative $5 million award from the Alzheimer's Drug Discovery Foundation (search) (ADDF (search)) to accelerate development of its lead therapeutic candidate, MITI-101 (search). The first-in-class program is designed to target immune pathways (search) driving neuroinflammation (search) and neurodegeneration (search) in Alzheimer's disease (search), positioning the company at the forefront of immune-focused therapeutic innovation.
The significant funding underscores growing scientific momentum around immune-mediated mechanisms in Alzheimer's disease (search), a field that has historically been under-targeted despite mounting evidence of its central role in disease progression.
Targeting Upstream Immune Mechanisms
MITI-101 (search) represents a novel approach to Alzheimer's treatment by intervening upstream in immune pathways (search) that contribute to sustained neuroinflammatory damage. While recent therapeutic advances have begun to address hallmark protein pathologies, mounting evidence indicates that immune dysregulation and chronic neuroinflammation (search) are central drivers of disease onset and progression.
"Alzheimer's disease (search) remains one of the most urgent and complex challenges in medicine," said Stevin Zorn, Chief Science Officer of MindImmune (search). "This support from the ADDF (search) empowers us to push the boundaries of immune biology in neurodegeneration (search) and rapidly advance MITI-101 (search) toward the clinic. We are building on a compelling body of science with the potential to redefine how we treat this devastating disease."
By modulating immune cell function (search), MindImmune (search) aims to address a fundamental component of neurodegeneration (search) that has been overlooked in traditional therapeutic approaches. The company's strategy focuses on identifying and modulating biological pathways that drive neuroinflammation (search) and disease progression, representing a new class of therapeutics designed to alter the trajectory of neurodegeneration.
Strategic Investment in Precision Medicine
The ADDF (search)'s investment reflects growing confidence in immune-focused strategies as a critical frontier in neurodegenerative disease treatment. Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF, emphasized the foundation's commitment to advancing novel therapeutic approaches.
"Advancing scientific innovation in Alzheimer's requires bold approaches that directly target the underlying biology and pathology of the disease," said Dr. Fillit. "Our investment in MindImmune (search) and its lead candidate, MITI-101 (search), reflects the ADDF (search)'s commitment to advancing novel therapies that address key biological drivers like neuroinflammation (search). Targeting these mechanisms will be essential to a broader precision medicine framework to effectively treat and ultimately prevent Alzheimer's."
Accelerating Clinical Development
The $5 million investment will support completion of critical translational studies and IND submission, as well as strategic planning for early clinical development. These efforts are designed to rapidly translate key scientific discoveries into meaningful patient impact, addressing the urgent need for effective Alzheimer's treatments.
Alzheimer's disease (search) affects millions globally, with pathological processes beginning years—often decades—before symptoms appear. This early intervention approach targeting immune mechanisms could potentially address disease progression at its source, offering hope for patients and families affected by this devastating condition.
The ADDF (search), founded in 1998, has awarded nearly $400 million to fund 792 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. The foundation's leadership and contributions have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD (search)®) to market, while fueling the current robust and diverse drug pipeline.
This award reinforces the ADDF (search)'s mission to catalyze high-potential research capable of transforming Alzheimer's treatment paradigms and highlights growing confidence in immune-focused strategies as a critical frontier in neurodegenerative disease.